Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

American Journal of Hematology

Volumn 90, Issue 4, 2015, Pages E60-E65

  Kastritis, Efstathios ^a   Roussou, Maria ^a   Gavriatopoulou, Maria ^a   Migkou, Magdalini ^a   Kalapanida, Despina ^a   Pamboucas, Constantinos ^a   Kaldara, Elisavet ^a   Ntalianis, Argyrios ^a   Psimenou, Erasmia ^a   Toumanidis, Savvas T ^a   Tasidou, Anna ^a   Terpos, Evangelos ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN LIGHT CHAIN; PYRAZINE DERIVATIVE; THALIDOMIDE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIMARY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; METABOLISM; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; BORONIC ACIDS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINES; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84925358614     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23936     Document Type: Article

References (48)

1. Comenzo RL. How I treat amyloidosis. Blood 2009;114:3147-3157.
2. Merlini G, Seldin DC, Gertz MA. Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924-1933.
3. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-470.
4. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351-1358.
5. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1/2 study. Blood 2011;118:865-873.
6. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28:1031-1037.
7. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 2007;109:492-496.
8. Lane T, Rannigan L, Foard D, et al. Alchemy-A large prospective "real world" study of chemotherapy in AL amyloidosis. ASH Annu Meeting Abstr 2011;118:992.
9. Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008;143:369-373.
10. Palladini G, Russo P, Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009;88:347-350.
11. Dinner S, Witteles W, Afghahi A, et al. Lenalidomide, melphalan and dexamethasone in an immunoglobulin light chain amyloidosis patient population with high rates of advanced cardiac involvement. Haematologica 2013;98:1593-1599.
12. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105:2949-2951.
13. Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457-464.
14. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: A multicenter phase 1/2 dose-escalation study. Blood 2010;116:4777-4782.
15. Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: Long-term results from a phase 2 trial. Blood 2012;119:4860-4867.
16. Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013;98:433-436.
17. Kastritis E, Terpos E, Roussou M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012;119:5384-5390.
18. Palladini G, Anesi E, Perfetti V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001;113:1044-1046.
19. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-2938.
20. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-4282.
21. Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study. Blood 2009;114:1489-1497.
22. Dubrey SW, Reece DE, Sanchorawala V, et al. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: Cardiac responses and overall effects. QJM 2011;104:957-970.
23. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-2445.
24. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881-1887.
25. Gertz M, Lacy M, Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymph 2008;49:36-41.
26. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011;86:12-18.
27. Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: Outcomes before and after 2006. Bone Marrow Transplant 2011;46:970-975.
28. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol 2012;30:4541-4549.
29. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-328.
30. Wechalekar AD, Schonl SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420-3427.
31. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391-4394.
32. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119:4387-4390.
33. Palladini G, Milani P, Foli A, et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: A matched case-control study on 174 patients. Leukemia 2014;28:2311-2316.
34. Venner CP, Gillmore JD, Sachchithanantham S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 2014;28:2304-2310.
35. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995.
36. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-3757.
37. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010;16:3426-3430.
38. Bianchi G, Oliva L, Cascio P, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009;113:3040-3049.
39. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: Targeted therapy? Haematologica 2007;92:1302-1307.
40. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-1093.
41. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787-788.
42. Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: Long-term results of a risk-adapted approach. Haematologica 2014;99:743-750.
43. Dietrich S, Schonl SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010;116:522-528.
44. Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (mayo clinic stage III). Haematologica 2014;99:1479-1485.
45. Cavallo F, Magarotto V, Offidani M, et al. Reduced Dose-intensity Subcutaneous Bortezomib Plus Prednisone (VP) or Plus Cyclophosfamide (VCP) or Plus Melphalan (VMP) for Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years of Age. ASH Annual Meeting 2013, Abstract 539.
46. Flinn I, Rifkin RM, Essell J, et al. Efficacy and Safety of Three Bortezomib-based Induction and Maintenance Regimens in Previously Untreated, Transplant-ineligible Multiple Myeloma (MM) Patients (Pts): Final Results from the Randomized, Phase 3b, US Community-based UPFRONT Study. ASH Annual Meeting 2013, Abstract 1966.
47. Magarotto V, Bringhen S, Offidani M, et al. A Randomized Phase 3 Trial of Melphalan-Lenalidomide-Prednisone (MPR) or Cyclophosphamide-Prednisone-Lenalidomide (CPR) vs. Lenalidomide Plus Dexamethsone (Rd) in Elderly Newly Diagnosed Multiple Myeloma Patients. ASH Annual Meeting 2013, Abstract 1966.
48. Tapan U, Seldin DC, Finn KT, et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood 2010;116:5071-5072.